Trial Profile
Use of the CIGB-247-V vaccine candidate in the treatment of Age-Related Macular Degeneration
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs CIGB 247 (Primary) ; Bevacizumab
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Adverse reactions
- Acronyms CELIMAR
- 14 Jan 2015 New trial record